title: [Clinical efficacy of intravenous L-carnitine in patients with right-sided heart failure induced by pulmonary arterial hypertension].
abstract: OBJECTIVE
  To investigate the efficacy of L-carnitine in patients with right-sided heart failure induced by pulmonary arterial hypertension (PAH).
  
  
  METHODS
  A total of 66 pulmonary arterial hypertension patients (14 idiopathic, 36 congenital heart disease associated and 16 connective-tissue disease associated PAH, WHO heart functional class III, n = 38 or IV, n = 28) were enrolled in this study and divided into control group (26 cases) and L-carnitine group (40 cases). All patients received conventional treatment according to guideline for treatment of right-sided heart failure. The patients in L-carnitine group received 5 g/d L-carnitine intravenously for seven days. Six-minute walking distance, WHO heart functional class, physical examination, and serum markers were evaluated at baseline and 7 days after enrollment.
  
  
  RESULTS
  Compared to the baseline, six-minute walking distance was significantly increased (75 m vs. 45 m, P < 0.05), WHO heart functional class significantly improved (improved 2 classes in 16 patients, improved 1 class in 13, no improved in 6, worsen in 5 vs. 3, 8, 9, 6 respectively in the control, P = 0.04), BNP level significant decreased (58.16 ng/L vs. 33.29 ng/L, P = 0.01) and systolic blood pressure significantly increased [8.1 mm Hg vs. 2.4 mm Hg (1 mm Hg = 0.133 kPa), P = 0.03] in L-carnitine group compared with those in control group. No patient was withdrawn from this study for safety reasons.
  
  
  CONCLUSIONS
  L-carnitine could improve short-term exercise capacity and WHO heart functional class in right-sided heart failure patients induced by PAH.
authors.affiliation: Department of Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University Medical School, Shanghai 200433, China.
authors.forename: Xi-Qi
authors.initials: XQ
authors.lastname: Xu
authors.forename: Zhi-Cheng
authors.initials: ZC
authors.lastname: Jing
authors.forename: Xin
authors.initials: X
authors.lastname: Jiang
authors.forename: Qin-Hua
authors.initials: QH
authors.lastname: Zhao
authors.forename: Jing
authors.initials: J
authors.lastname: He
authors.forename: Li-Zhi
authors.initials: LZ
authors.lastname: Dai
authors.forename: Wen-Hui
authors.initials: WH
authors.lastname: Wu
authors.forename: Yun
authors.initials: Y
authors.lastname: Li
authors.forename: Juan
authors.initials: J
authors.lastname: Yao
mesh_terms: D000328:Adult; D002331:Carnitine / Q000627:therapeutic use*; D005080:Exercise Test; D065627:Familial Primary Pulmonary Hypertension; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D006976:Hypertension, Pulmonary / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D002331:Carnitine